Compare Amphastar Pharmaceuticals Inc (AMPH) vs Hewlett Packard Enterprise Co (HPE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amphastar Pharmaceuticals Inc vs Hewlett Packard Enterprise Co — how do they compare? Amphastar Pharmaceuticals Inc trades at $20.39 (market cap $863.95M), while Hewlett Packard Enterprise Co trades at $55.01 (market cap $72.41B). The key difference: Hewlett Packard Enterprise Co is far larger — about 83.8× Amphastar Pharmaceuticals Inc's market cap, and Hewlett Packard Enterprise Co pays a 1.04% dividend while Amphastar Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMPH | HPE | |
|---|---|---|
Market Cap | $863.95M | $72.41B |
Sector | Health | Technology |
52-Week High | $30.81 | $56.14 |
52-Week Low | $16.87 | $20.01 |
Enterprise Value | $1.26B | $88.36B |
Dividend Yield | — | 1.04% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMPH trades at $20.78, up 4.9% today, with a bullish technical signal supported by moving averages. The stock shows mixed earnings performance with Q2 2026 beating estimates but Q1 and Q4 2025 missing. Fundamentals remain solid with a 10.76% net margin and reasonable valuation at 12.02 P/E. Recent news highlights Q2 2026 results and strategic shift toward proprietary drugs.
Outlook is cautiously optimistic with growth supported by new product launches, though regulatory risks and earnings volatility pose challenges. Analyst sentiment is mixed with 25% buy ratings but majority hold recommendations. The stock offers value but requires monitoring of FDA developments and earnings consistency.
HPE stock trades at $53.22, up 1.49% today, near its pivot point of $53, with bullish moving averages but overbought RSI signals. Recent earnings beats, including Q1 2026 EPS of $0.79 versus $0.535 expected, and a Morgan Stanley upgrade on August 10, 2026, highlight AI infrastructure demand strength. Revenue grew to $34.30B in 2025, though net income fell sharply to $57M due to high investing cash outflows.
The outlook is positive with a consensus price target of $69.81, implying 31% upside, supported by AI server trends. Risks include volatile cash flows, rising debt-to-asset ratio to 29.48% in 2025, and intense competition. Investors should weigh growth potential against execution risks in a high-valuation environment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amphastar Pharmaceuticals Inc
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →About Hewlett Packard Enterprise Co
Hewlett Packard Enterprise is an information technology vendor that provides hardware and software to enterprises. Its primary product lines are compute servers, storage arrays, and networking equipment.
Read more on HPE →
